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ABSTRACT
Toxoplasmic encephalitis (TE) is caused by Toxoplasma gondii infection and can be a life-
threatening disease in immunocompromised patients. This study evaluated the rate of relapse 
associated with pyrimethamine-based maintenance therapy (i.e. secondary prophylaxis) in 
patients with human immunodeficiency virus (HIV) or AIDs treated prior to and after the common 
use (i.e. 1996) of highly active antiretroviral therapy (HAART) (pre-HAART and post-HAART, 
respectively). PubMed, Google Scholar, and Cochrane databases were searched to 6 June 2016 
using search terms: pyrimethamine, Daraprim, Fansidar, Metakelfin, Fansimef, 5-(4-chlorophenyl)-
6-ethyl-2,4-pyrimidinediamine, encephalitis, cerebral, toxoplasmosis, toxoplasmic, and gondii. 
Single-arm cohort, retrospective, and randomized studies were included. Twenty-six studies 
with 1,596 patients were included in the analysis; twenty pre-HAART (n = 1,228) studies and 
six post-HAART (n = 368) were performed. Pooled proportions test for pyrimethamine-based 
therapy from pre-HAART studies indicated a relapse rate of 19.2% and 18.9% from the fixed-
effects and random-effects models, respectively. The relapse rate in the post-HAART studies 
was 11.1% (fixed and random effects). Continuous therapy was suggestive of lower incidence of 
relapse compared with intermittent therapy in the pre-HAART era (range, 18.7 to 17.3% vs. 20.9 
to 25.6%, respectively). These findings indicate that the likelihood of relapse associated with 
pyrimethamine-based therepy in patients with HIV and TE decreased after the introduction of 
HAART to approximately 11%. The findings have important implications as relapse may affect a 
patient’s disease severity and prognosis, increase utilization of health care resources, and result 
in additional health care expenditure.
Introduction
Toxoplasmic encephalitis (TE) results from infection 
by Toxoplasma gondii (T. gondii), a ubiquitous obligate 
intracellular parasite with a worldwide prevalence that 
infects humans and other warm-blooded animals [1]. 
Approximately, one third of the population worldwide 
is chronically infected with T. gondii [2], T. gondii sero-
prevalence varies world wide. In the United States, it is 
estimated that 22.5% of the population 12  years and 
older are infected with the parasite [3]. It is estimated 
that 6.7% of people in Korea, 12.3% in China, 23.9% in 
Nigeria, 46% in Tanzania, and 47% in the rural areas of 
France are seropostive for T. gondii [4−8]. In Brazil, up 
to 50% of elementary school children and 50 to 80% of 
women of child-bearing age have antibodies to T. gon-
dii [9]. T. gondii infection has two phases: active (acute) 
which is characterized by severe symptoms; and latent 
(dormant) which is typified by life-long persistence of 
cysts in tissues [10]. TE typically results from reactivation 
of the dormant organism [11].
TE is one of the most common opportunistic infec-
tions of the central nervous system (CNS) in patients with 
acquired immune deficiency syndrome (AIDS) world-
wide, and in the United States between 10 and 40% of 
HIV-infected individuals have antibodies against T.  gondii 
[12−14]. TE is a life-threatening disease,  especially for 
immunocompromised patients, such as those with AIDS 
[13,15]. Encephalitis causes significant  morbidity and 
mortality in patients with HIV, and toxoplasmosis was found 
to be the most common specified  encephalitis-associated 
hospitalizations in patients with HIV [16].
The National Institutes of Health (NIH) Guidelines rec-
ommend the use of pyrimethamine, sulfadiazine, and 
leucovorin for the initial treatment of TE in HIV-infected 
pateints [17]. Pyrimethamine and sulfadiazine are 
thought to act synergistically to inhibit T. gondii prolifer-
ation and survival by blocking the folate metabolic path-
way and consequently DNA synthesis [11]. Leucovorin is 
added to reduce potential adverse reactions associated 
with folic acid metabolism [11]. In case of allergy to sulfa 
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retrospective longitudinal studies. Studies had to report 
relapse of TE during maintenance therapy in patients 
with AIDS or HIV. All studies had to be published in 
peer-reviewed journals in English, Spanish, Portugueuse, 
or French. Studies that only provided relapse rates during 
acute treatment were rejected. Review articles, letters, 
comments, editorials, case reports, proceedings, per-
sonal communications, and preclinical studies were also 
excluded. Study eligibility for inclusion was determined 
by two independent reviewers, and in cases of uncer-
tainty, a third reviewer was consulted.
Data extraction
Double data extraction was performed on all included 
studies to ensure data consistency. Discrepencies in 
extracted data between the two independent reviewers 
were resolved by a third reviewer. Non-English studies 
were reviewed by native speakers, and validated by a sec-
ond reviewer for extracted data using Google Translator. 
The following data were extracted from the studies when 
reported: first author, publication year, study design, 
acute and maintence treatment regimens, number of 
patients, incidence of relapse, and duration of follow-up. 
For studies with insufficient reported data, we attempted 
to contact authors to obtain complete data. Studies were 
classified as being pre-HAART or post-HAART based 
on a cut-off date of 1996 for the conduct of the study 
(not publication date). The year 1996 is when the use of 
HAART therapy became widely available and dramat-
ically decreased mortality of patients with AIDS (from 
29.4/100 person years in 1995 to 8.8 per 100 person-years 
in the second quarter of 1997) [25]. HAART status was 
verified by patient baseline characteristics and current 
treatments reported, although not all patients treated in 
the HAART period were receiving antiretroviral therapy. 
The abstracts were screened and data were extracted by 
the authors MPC and EG.
Quality assessment
The quality of the included studies was evaluated using 
Study Quality Assessment Tools of the National Heart, 
Lung, and Blood Institute of the NIH for quality assess-
ment of observational cohort, cross-sectional, before–




The primary outcome was rate of relapse during 
pyrimethamine-based maintenance therapy. The sec-
ondary outcome was rate of relapse with continuous 
(daily) or intermittent (two to three times per week) 
pyrimethamine-based therapy. For each outcome, rates 
in each study were transformed using the Freeman-Tukey 
drugs, the recommended alternative treatment is a com-
bination of pyrimethamine, clindamycin, and leucovorin 
[17]. Sulfa drug allergies are observed in about 5% of the 
population and up to 30% of HIV-infected patients [18].
The incidence of TE in patients infected with HIV is 
closely related to the progression of immune deficiency 
and a reduction in CD4 T lymphocyte cell counts. TE is 
rare in patients with CD4 cell counts >200 cells/μL, while 
the risk of TE is greatest in patients with CD4 counts 
<50 cells/μL [19]. It is recommended by the NIH/AIDS 
Guidelines to continue chronic maintenance treatment 
in patients who have responded to initial TE therapy until 
the person remains asymptomatic and their CD4 counts 
are >200 cells/μL after highly active anti-retroviral ther-
apy (HAART) for for six months [17].
Despite treatment efforts, a percentage of patients 
receiving maintenance therapy for TE will experience a 
relapse [13]. Relapse of TE can have significant implica-
tions for patients who often develop new lesions in areas 
of the brain previously free of infection [20], and for pro-
viders and the health care system as a relapse can result 
in rehospitalization and/or change in therapy.
Previous meta-analyses have assessed the efficacy 
and safety of pyrimethamine for acute TE [21−23]; 
however, the incidence of relapse during maintenance 
therapy following resolution of acute TE has not been 
assessed [21−24]. Therefore, to gain greater insight into 
the risk of TE relapse, we performed a systematic review 
and meta-analysis to evaluate the incidence of relapse 
associated with pyrimethamine-based maintenance 
therapy (i.e. secondary prophylaxis) in persons with 
HIV/AIDS. We also investigated whether the likelihood 
of relapse changed following the introduction of HAART 
therapy in the mid-1990s. This was of interest because 
HAART has greatly reduced AIDS-related morbidity and 
mortality and decreased the incidence of opportunis-
tic infections in HIV-infected patients [25]. The impact 
of HAART on the incidence of relapse of TE in patients 
with HIV is not clear. In order to incorporate the broad-
est scope of available evidence, the analysis protocol 
allowed for inclusion of studies of varying design, such 




The study was performed in accordance with PRISMA 
[26], and the protocol can be found in Supplemental 
Material. PubMed, Google Scholar and Cochrane data-
bases were searched up to 6 June 2016 using the fol-
lowing search terms: pyrimethamine, Daraprim, Fansidar, 
Metakelfin, Fansimef, 5-(4-chlorophenyl)-6-ethyl-2,4-py-
rimidinediamine, encephalitis, cerebral, toxoplasmosis, 
toxoplasmic, gondii. Eligible studies included randomized 
controlled studies, observational prospective studies, and 
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double arcsine method. This transformation stabilizes the 
variance estimates, which is important for proportions 
close to 0 or 1 [28]. Rates were then pooled using both 
fixed-effect and random-effects meta-analysis models. 
The fixed-effect model was performed using the inverse 
variance method and the random-effects model using 
the DerSimonian and Laird method, with the estimate 
of heterogeneity taken from the inverse variance model 
[29]. Heterogeneity across studies was assessed by 
quantifying I2 inconsistency scores [30]. I2 describes the 
percentage variation across studies attributed to hetero-
geneity rather than chance. Low I2 values (≤50%) suggest 
limited heterogeneity between studies, and I2 values >50 
to 75% indicate moderate heterogeneity. Values >75% 
suggest high heterogeneity and the need to consider 
estimates from random-effects models [30]. The analysis 
was performed using StatsDirect (Altrincham, UK) statis-
tical program version 2.8.0 (27 October 2013). For ease of 
interpretating, the reported proportions were converted 
to percentages. Because the studies are non-compara-
tive, we assessed active treatment arms independently; 
therefore, no comparative statistics were performed and 
only the combined relapse rate is reported.
Bias of the results was evaluated by the funnel plot 
and the Egger’s test [31,32]. In the absence of bias, the 
graph is a symmetrical inverted funnel, and if there is 
bias, the funnel plot will appear asymmetrical [31,32]. 
Reporting bias was assessed for the pre-HAART analysis, 
but not the post-HAART analysis as the minumum stud-
ies for this analysis should be >10; below this value, the 




Of 1,307 studies initially identified, 1,121 were excluded 
following the ‘removal of duplicates and an initial 
abstract screen (Figure 1). After full-text review, an addi-
tional 160 were removed for only describing methodol-
ogy or a study protocol, being a pre-clinical study, being 
a case report, not reporting relapse rates, being an epi-
demiology or health care cost study, not evaluating TE, 
not administering pyrimethamine-based regimens, not 
investigating toxoplasmosis, describing finding for pri-
mary prophylaxis of TE, being a review article, not being 
published in English, French, Spanish, or Portugeuse, or 
evaluting an inappropriate patient population.
Study characteristics
Twenty-six studies were included in the analysis with 
1,596 patients (Tables 1 and 2). Twenty reported findings 
from studies that were performed up to 1996 (n = 1,228) 
(Table 1) [34−51], and six described results of studies per-
formed after 1996 (n = 368) (Table 2) [52−57].
Full-text articles excluded and 
reasons 
(n=160) 
Methods development/preclinical: 6 
Case report: 6 
Did no report relapse: 38 
Epidemiology: 10 
Health care cost: 2 
Not TE: 28 
Not pyrimethamine: 14 
Not toxoplasmosis: 4 
Primary prophylaxis: 29 
Protocol description: 1 
Reviews: 21 
Not English, French, Spanish, 
Portuguese: 1 
Inappropriate population: 1 
Records excluded 
(n=1121) 
Studies included in 
analysis 
(n = 26) 
Records identified through 
database searching 
(n=1295) 
Additional records identified through 
other sources 
(n=12) 
Duplicates removal and initial abstract 
screening 
(n=186) 
Full-text articles assessed 
for eligibility 
(n=186) 
Figure 1. search flow diagram.
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Study designs differed across both pre- and post-
HAART studies. The pre-HAART studies included three 
randomized, six prospective, and 11 retrospective stud-
ies (Table 1), and the post-HAART studies included two 
randomized, two prospective, and two retrospective 
studies (Table 2). All studies included patients with AIDS 
or infected with HIV and who had received maintenance 
therapy for TE.
Among the studies, the pyrimethamine-based treat-
ment regimens were heterogeneous, both for acute and 
maintenance therapy (Tables 1 and 2). In the pre- and 
post-HAART groups, the most common therapy both for 
acute and maintenance therapy was the combination 
of pyrimethamine and sulfadiazine. Other investigated 
pyrimethamine-based regimens included clindamy-
cin, sulphamethopyrazine, sulfadoxine, clarithromycin, 
and atovaquone. Four studies in the pre-HAART group 
[41,42,45,47] and two in the post-HAART group [52,55] 
administered pyrimethamine alone for maintenance 
therapy. Most studies co-administered folinic acid 
(leucovorin) with pyrimethamine for acute therapy; 
only four did not report co-administering folinic acid 
with pyrimethamine – three in the pre-HAART group 
[35,58,59] and one in the post-HAART group [52]. Of the 
included studies, 11 did not report co-administering 
folinic acid with pyrimethamine during maintenance 
therapy [34,35,38,41,45,47,49,51,52,54,60].
The follow-up for pre-HAART studies ranged from 3 
months to 7 years and for the post-HAART studies from 
4 to 22 months. For the pre-HAART studies, the rate of 
relapse ranged from 0 to 67% and for the post-HAART 
studies ranged from 0 to 12.9%.
Quality assessment
The majority of included studies obtained scores of 
medium–to-low quality due the varied trial designs. 
Despite the overall quality assessment, the relapse data 
reported were of sufficient quality for inclusion in the 
proportions analysis.
Meta-analysis
The pooled proportions test for pyrimethamine-based 
therapy in pre-HAART studies indicated a relapse rate of 
19.2% and 18.9% from the fixed-effects and random-ef-
fects models, respectively (Table 3 and Figure 2 and 
Figure 3). In the post-HAART period, the pooled propor-
tions relapse rate was 11.1%, and was the same from 
both the fixed- and random-effect models due to limited 
heterogeneity in the data (I2 = 0%) (Table 3 and Figure 4).
Six studies reported relapse rates of patients who 
received intermittent pyrimethamine-based ther-
apy (two to three times per week); five pre-HAART 
[40,43,45,49,61] and one post-HAART [56]. We evalu-
ated the rate of relapse in these studies compared with 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PATHOGENS AND GLOBAL HEALTH  39
asymmetry (Eggar bias: 3.12386 (95% CI = 1.196098 to 
5.051621); P = 0.0031).
Discussion
This systematic review and meta-analysis assessed the 
incidence of TE relapse following pyrimethamine-based 
therapy in patients with HIV or AIDS. The anlysis found 
that the incidence of relapse was higher in pre-HAART 
(19.2% for fixed effect model and 18.9% for random 
effect model) compared with post-HAART (11.1% for 
both fixed- and random-effect models). The drop in the 
incidence of relapse with the use of HAART therapy is 
consistent with the impact of HAART on the immune 
rate with intermittent pyrimethamine-based therapies 
in pre-HAART studies was 20.9% from the fixed-effect 
and 25.6% from the random-effect models, and for con-
tinous therapy was 18.7–17.3%, respectively (Table 3). 
The rates for continuous therapy for post-HAART were 
10.5%. Intermittent therapy was not analyzed in the post-
HAART studies as only one study [56] evaluated this type 
of treatment regimen.
Analysis of reporting bias
Funnel plot analysis was performed for the pre-HAART 
studies (Figure 5). The analysis indicated the presence 
of reporting bias as indicated by significant funnel plot 
Table 3. Pyrimethamine-based maintenance therapy: relapse rates in pre-haaRt and post-haaRt period.
aanalysis was not performed as only one study in the post-haaRt timeframe evaluated intermittent pyrimethamine-based therapy.
CI, confidence interval; I2, inconsistency.
  Proportions Fixed-effect Proportions Random-effect I2
Pre-haaRt 0.192 (95% CI = 0.167 to 0.218) 0.189 (95% CI = 0.137 to 0.247) 76.4% (95% CI = 62.8 to 83.5%)
Post-haaRt 0.111 (95% CI = 0.078 to 0.149) 0.111 (95% CI = 0.078 to 0.149) 0% (95% CI = 0 to 61%)
Intermittent Pre-haaRt 0.209 (95% CI = 0.139 to 0.287) 0.256 (95% CI = 0.104 to 0.445) 72.9% (95% CI = 17.9 to 86.7%)
Intermittent Post-haaRta – –  
Continuous Pre-haaRt 0.187 (95% CI = 0.161 to 0.214) 0.173 (95% CI = 0.119 to 0.234) 77.5% (95% CI = 64.4 to 84.3%)
Continuous Post-haaRt 0.105 (95% CI = 0.069 to 0.146) 0.105 (95% CI = 0.069 to 0.146) 0% (95% CI = 0 to 61%)
Figure 2. Forest plot of fixed for analysis of pre-haaRt studies.
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combination. A similar search identified only five stud-
ies that evaluated TMP-SMX for maintenance therapy 
and reported relapse of HIV-infected patients with TE 
[48,62−65], four of which were performed post-1996 
[62−65]. Across the five studies, the rate of TE relapse 
ranged from 3 to 39%.
Evidence from randomized controlled trials serve as 
the gold-standard for studies to be included in meta-anal-
yses to reduce bias in the results. However, challenges 
exist in applying randomized control trial results to the 
real-world clinical setting due to differences between 
subjects recruited and the types of patients encountered 
in clinical practice [66]. We included both prospective 
observational and retrospective studies due to the short-
age of available randomized studies with pyrimethamine 
relative to the number of other study designs in TE. The 
inclusion of these studies in our analysis broadens the 
range of evidence and may improve the generalizability 
of the findings. This approach is consistent with other 
health service researchers who have included obser-
vational study designs in meta-analyses, and has been 
applied in other disease areas [67,68].
The analysis described here has several limitations 
that are worth considering. Significant heterogeneity 
status of patients with HIV or AIDs. To our knowledge, this 
is the first meta-analysis to evaluate the rate of relapse 
of TE in HIV-infected or AIDS patients, and specifically 
illustrates the benefits of HAART therapy for preventing 
relapse.
Relapse during maintenance therapy may result 
from a number of causes including treatment efficacy, 
dosing regimen, patient characteristics, and treatment 
adherence. The importance of the dosing regimen is indi-
cated by our results that sugggest intermittent therapy 
administered two to three times per week was associated 
with a higher relapse rate compared with continuous 
therapy, and supports the NIH Guidelines of daily dos-
ing of pyrimethamine plus sulfadiazine for maintenance 
treatment [17].
The analysis described here focused on pyrimeth-
amine-based therapy for the prevention of relapse due 
to the extensive history of the use of pyrimethamine in 
the clinic and the significant number of observational 
and retrospective clinical studies that have evaluated 
the effect of pyrimethamine-based therapy in treat-
ing TE. Much less-published information is available 
regarding the use of other off-label treatments for TE, 
such as the trimethoprim–sulfamethoxazole (TMP-SMX) 
Figure 3. Forest plot of random effect model for analysis of pre-haaRt studies.
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therefore, it was not feasible to infer whether differences 
in relapse rates reported here are significantly different.
This study comprehensively evaluated the relapse rate 
of TE in patients with HIV or AIDS who received pyrimeth-
amine-based maintenance therapy. The findings indicate 
that the incidence of relapse decreased after the intro-
duction of HAART. The reduction in relapse following the 
introduction of HAART is consistent with the ability of 
HAART to control HIV infection. In addition, this study 
suggests that daily pyrimethamine-based maintenance 
therapy is likely more efficacious in preventing TE relapse 
compared with intermittent therapy. These findings have 
important medical and cost implications as relapse may 
affect a patient’s prognosis and healthcare resource uti-
lization, and result in additional healthcare expenditure.
across studies was present with respect to study design, 
dosing regimen, and defintion of relapse, and the major-
ity of studies were of mediumto-low quality. Also, the size 
of the patient population for the post-HAART analysis 
was small. Furthermore, not all patients were receiving 
HAART therapy for various reasons, and the results were 
not presented by HAART precluding an assessment of 
how this would influence results. Although, based on 
the analysis described here it is likely to have dimin-
ished effectiveness and increased likelihood of relapse. 
Reporting bias was also present which may have con-
founded the results. In addition, duration of follow-up 
varied between studies which could influence the rate 
of relapse. It is also important to emphasize that the 
proportions reported here are independently evaluated; 
Figure 4. Forest plot of (a) fixed and (b) random effect model for analysis of post-haaRt studies.
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